Increase efficiencies and productivity by automating core reporting tasks for medical writing.
Automate core regulatory report documents across the CTD pyramid and dramatically accelerate submission timelines.
NEW YORK, NY – September 18 – Claret Capital Partners has announced a €10 million growth investment in Yseop, a global leader in Generative AI for life sciences. The funding will support Yseop’s international expansion and accelerate the development of its enterprise-grade platform for regulatory content automation.
Yseop’s flagship product, Yseop Copilot, is already deployed across leading pharmaceutical organizations including Eli Lilly and Novartis. The platform streamlines the creation of complex clinical and regulatory documentation such as clinical study reports (CSRs), patient narratives, and CMC submissions. This allows teams to produce high-quality, compliant content with greater speed and consistency.
Built for regulated environments, Yseop’s Composite AI architecture combines large language models with business logic and domain rules to ensure outputs are scientifically aligned, compliant, and audit-ready. Its native integration with Microsoft Word and Veeva Vault allows life sciences organizations to embed automation directly into their existing workflows.
Antony Baker, Senior Investment Director at Claret Capital Partners, said:
“We are delighted to invest in Yseop. Their team is building an exciting, highly innovative business, with a leading AI-powered platform that is helping some of the biggest names in pharma to deliver therapies faster to market. We very much look forward to being part of the growth journey from here.”
Emmanuel Walckenaer, CEO of Yseop, added:
“This investment comes at a pivotal moment for our industry. As regulatory complexity increases and timelines tighten, the need for intelligent automation is only growing. Claret’s support allows us to accelerate innovation and deliver even greater value to our customers.”
With this new funding, Yseop will continue to scale adoption, enhance product capabilities, and expand globally to meet growing demand for accurate, efficient, and compliant AI solutions across life sciences.